Interaction between compound genetic risk for schizophrenia and high birth weight contributes to social anhedonia and schizophrenia in women

Johanna Liuhanen, Jaana Suvisaari, Eero Kajantie, Jouko Miettunen, Antti-Pekka Sarin, Marjo-Riitta Järvelin, Jouko Lönnqvist, Juha Veijola, Tiina Paunio

A R T I C L E   I N F O

Keywords:
Gene-environment interaction
Schizophrenia

A B S T R A C T

Schizophrenia is a highly heritable disease, but despite extensive study, its genetic background remains unresolved. The lack of environmental measures in genetic studies may offer some explanation. In recent Finnish studies, high birth weight was found to increase the risk for familial schizophrenia. We examined the interaction between a polygenic risk score for schizophrenia and high birth weight on social anhedonia and schizophrenia in a general population birth cohort. The study sample included 4223 participants from the 1966 Northern Finland Birth Cohort. As a replication sample we used 256 participants from a systematically collected sample of Finnish schizophrenia families. The polygenic risk score comprised of variants published in the large genome-wide meta-analysis for schizophrenia. We found the association between the polygenic risk score and social anhedonia stronger among those with high birth weight, and the same phenomenon was seen for schizophrenia among women, suggesting a gene-environment interaction. Similar results were found within the replication sample. Our results suggest a role for gene-environment interactions in assessing the risk of schizophrenia. Failure to take environmental effects into account may be one of the reasons why identifying significant SNPs for schizophrenia in genome-wide studies has been challenging.

1. Introduction

Schizophrenia is a highly heritable mental disorder - its heritability estimate is up to 80% (Sullivan et al., 2003) - and its genetic background has been studied intensively. Nonetheless, the genetic architecture behind schizophrenia is not well understood, as a substantial proportion of its genetic background remains unresolved. It has been shown that thousands of common single nucleotide variants, each with a minor effect, might cumulatively explain one-third of the variance in the disease risk (International Schizophrenia Consortium et al., 2009).

Several hypotheses have been proposed to explain the unexplained portion of the heritability estimate. One such hypothesis is gene-environment interactions (G x E) (van Dongen and Boomsma, 2013). Environment clearly plays a role in the development of schizophrenia (Tandon et al., 2008), and, like genetic effects, environmental effects have shown wide heterogeneity across individuals as well. Genes do not operate in isolation of the environment and it is highly plausible that we will not fully understand the genetics of schizophrenia if the environment is not also taken into consideration. A proof of principle for gene-environment interactions in schizophrenia has been provided by candidate gene studies (Modinos et al., 2013), and in studies where familial background has been used as a measure of genetic liability (e.g.
Clarke et al., 2009). To our knowledge there is one published genome-wide gene-environment interaction study (GEWIS) on schizophrenia (Borglum et al., 2014). In that study Borglum and colleagues (2014) found a significant interaction between a SNP on CTNNA3 and maternal cytomegalovirus infection on schizophrenia. To date, G x E studies have not yet fully exploited the genetic knowledge gained from large genome-wide meta-analyses. To our knowledge there is one published study that studied G x E with polygenic risk scores on schizophrenia (Trointa et al., 2016).

The prenatal environment is one of the environments most consistently related to schizophrenia. One of the most widely used markers of prenatal environment is birth weight. Both low and high birth weight have been related to the risk of schizophrenia (Moilanen et al., 2010). While the effect of low birth weight seems to be consistent across cohorts (Abel et al., 2010), high birth weight tends to be a risk factor in older cohorts when, for example, gestational diabetes was not always systematically screened nor treated, induction of delivery was more rare and based on less accurate estimation of fetal weight, and high-quality obstetric care was not always available if a large birth weight caused problems during delivery (Moilanen et al., 2010; Wegelius et al., 2011). The variable associations with high birth weight suggest that it is particularly relevant with respect to gene-environment interactions. Accordingly, in two recent Finnish studies, high birth weight was found to considerably increase the risk for schizophrenia in already high-risk families (Keskinnen et al., 2013; Wegelius et al., 2011). Keskinnen and coauthors (2013) observed that high birth weight, not low, increased the risk for schizophrenia if the participant's parents had a history of psychosis. This suggests that genetic liability for schizophrenia, as indicated by parental psychosis, might interact with high birth weight in the development of schizophrenia.

Our aim was to examine the interaction between a polygenic risk score for schizophrenia and high birth weight on social anhedonia, an intermediate phenotype reflecting schizophrenia liability (Cohen et al., 2011; Miettunen et al., 2011; Kwapił, 1998), and schizophrenia diagnosis in a general population birth cohort. We hypothesized that having higher genetic risk score together with high birth weight would be associated with higher scores on social anhedonia and with higher risk for schizophrenia.

2. Methods

2.1. Study sample

The study sample (n = 4223) was derived from the Northern Finland Birth Cohort 1966 (NFBC1966), which is an unselected birth cohort consisting of 12,058 live-born children in Northern Finland (Rantakallio, 1969). The cohort represents the general population by covering 96.3% of all births during year 1966 in the provinces of Lapland and Oulu. The cohort has been prospectively followed from the perinatal period to adulthood, and the study sample consists of those participants of the 31-year follow-up study who had DNA and other data used in the study available. Attrition analysis of the 31-year follow-up has been described elsewhere (Haapea et al., 2008). The study has been approved by The Ethics Committee of the Northern Ostrobotnia Hospital District, and all participants gave written consent.

2.2. Replication sample

The replication sample (n = 256) was derived from a systematically collected sample of Finnish schizophrenia families, the Schizophrenia family sample (FSZ). Families were identified through a search of nationwide health care and population registries. All individuals born in Finland between 1940 and 1976 were screened for hospitalization during the period from 1969 to 1998 (Hospital Discharge Register), for use of free outpatient antipsychotic medication (Medication Reimbursement Register), or disability pension (Pension Register) due to schizophrenia, schizoaffective disorder, or schizophreniform disorder. Pedigrees were constructed by linking the personal identification numbers of the affected individuals to their parents and siblings, derived from the Population Register Centre. Two samples of subjects were contacted: 1) the first sample (All Finland) consisted of families with at least two siblings with schizophrenia and their first-degree relatives from the whole geographical area of Finland; and 2) the second sample (Internal Isolate) comprised patients and their relatives from families with at least one member with schizophrenia from Kuusamo, a historically isolated region in the north-eastern part of the country with an exceptionally high lifetime risk of schizophrenia (Hovatta et al., 1999; Ararjärv et al., 2005). The study has been approved by the Ethics Committee of the Hospital District of Helsinki and Uusimaa, and all participants gave written consent.

The total sample consists of 3335 individuals with DNA samples, but availability of birth weight and social anhedonia data limits the number of participants used for the replication; we had 256 and 133 individuals for the schizophrenia and social anhedonia analysis, respectively.

2.3. Measures

2.3.1. Social anhedonia

Social anhedonia was self-rated using the revised Social Anhedonia Scale (Chapman et al., 1976). The scale includes 40 true/false questions assessing one’s interest in social interaction. Sample items of the scale are: “Having close friends is not as important as many people say.” and “People sometimes think I am shy when I really just want to be left alone.” The distribution of the social anhedonia scale was positively skewed in both samples and we performed a square-root transformation for the scale. Study Sample. Social anhedonia was assessed as a part of the cohort’s 31-year follow-up in 1997. The psychometric properties of the scale in this cohort have been described elsewhere (Miettunen et al., 2010). Replication Sample. Social anhedonia was only measured in a subsample derived from the All Finland Sample during the data collection in 1999–2001. The reliability of the scale in this sample has been reported earlier (Kuba et al., 2011).

2.3.2. Schizophrenia spectrum diagnosis

Schizophrenia spectrum diagnosis in the Study Sample was assessed using several national registers (the Finnish Hospital Discharge Register and national registers of the Finnish Social Insurance Institute) and clinical interviews. The diagnoses were made according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, revised 3rd edition (DSM-III-R). In order to increase the power of our population-based study, we included as cases all participants who had either schizophrenia diagnosis or a diagnosis belonging to the schizophrenia spectrum (schizoaffective, schizophreniform, delusional disorder). Replication Sample. Schizophrenia diagnoses were made according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). All available inpatient and outpatient records were collected from participants and their relatives, if they had any psychiatric diagnosis according to the registers (Hospital Discharge Register, Medication Reimbursement Register, and Pension Register). Some of the participants were also interviewed with the Structured Clinical Interview for DSM-IV diagnosis. Two psychiatrists blind to the family structure estimated independently the best-estimate lifetime diagnosis according to the criteria of the DSM-IV. In case of any disagreement, a third reviewer was used. Consensus diagnoses were made based on these independent estimates.

2.3.3. Birth weight

Study Sample. Information on birth weight was collected from child welfare clinic registries and with questionnaires filled in by the mothers during the years 1965–1967. We dichotomized birth weight as “more than 4 kg” and “4 kg or less” based on earlier Finnish findings on the
association between birth weight and schizophrenia (Wegelius et al., 2011). The mean birth weight for gestational week 40 in the total Northern Finland 1966 birth cohort was 3460 g (Rantarallio, 1973), while the current Finnish reference gives mean values for birth weight at gestational age of 40 weeks as 3766 g and 3624 g for singleton boys and girls, respectively (Sankilampi et al., 2013). Therefore, using the cut-off of 4 kg is reasonable with the relatively old cohorts we studied, while a higher cut-off might be better in more recent cohorts. Replication Sample. Data on birth weight was obtained from registries kept by obstetric and healthcare clinics. Because of the limited number of participants in our replication study, birth weight was not categorized as “low” (i.e. less than 2.5 kg) or “high” (i.e. more than 4 kg), but studied as a continuous variable.

2.3.5. Genetic risk score

Study Sample. Genotypes were obtained from genome-wide data genotyped with Illumina Infinium 370cmvDuo platform at the Broad Institute, USA. Detailed description of the genotyping and quality control procedure has been described earlier (Sabatti et al., 2009). The genetic risk score was based on 8 SNPs published in the genome-wide meta-analysis in 2011 (Schizophrenia Psychiatric Genome-Wide Association Study GWAS Consortium, 2011). Two of these variants were genotyped (rs10503253 and rs7004633) and six were imputed (rs1625579, rs17662626, rs2021722, rs7914558, rs11191580, and rs548181; HapMap2 as the reference). The broader genetic risk score comprised of 128 variants recently published in a large meta-analysis (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) was based on 15 genotyped and 113 imputed variants (1000 Genomes as the reference). Replication Sample. Genotypes were sampled for the eight SNPs (rs10503253, rs7004633, rs1625579, rs17662626, rs2021722, rs7914558, rs11191580, and rs548181) with homogeneous mass extension using the MassARRAY System (Sequenom, San Diego, California). Genotyping was performed by following the manufacturer’s guidelines in 384-well plates using a total reaction volume of 5 µl including 20 ng of genomic DNA. For quality control, duplicate DNA samples, control DNA, and water controls were included in each plate. We did not have genome-wide data available for the replication sample, and accordingly we were not able to calculate the broader genetic risk score of 128 variants in this sample.

2.3.6. Genetic risk score / 128 variants

We also calculated a broader genetic risk score of 128 variants recently reported in a large GWAS meta-analysis for schizophrenia (Schizophrenia Psychiatric Genome-Wide Association Study GWAS Consortium, 2014) in the study sample. Of the 128 variants, one imputed variant did not pass the imputation quality threshold (0.7) we had set, and was therefore dropped out of the score (chr1: rs77149735). Therefore, we calculated the genetic risk score from 127 variants using the following formula:

\[
\text{Genetic Risk Score} = \sum_{i=1}^{127} \left[ 2xp(A_i) + p(A_i, B) \right] \times \log (\text{OR}),
\]

where OR = odds ratio for the reference allele, p = probability for the genotype, A = the reference allele of the variant, and B = the alternative allele of the variant.

2.4. Statistical analysis

Study Sample. We used linear and logistic regression in analyzing the gene-environment interactions on social anhedonia, and schizophrenia spectrum diagnosis, respectively. In fully adjusted interaction models we had the following covariates: sex, gestational age and three first main principal components calculated from the genome-wide genotype data (Price et al., 2006) to control for population stratification. All the participants were of the same age (born in 1966), and accordingly we did not use age as a covariate. We excluded participants who had other psychoses than a schizophrenia spectrum disorder (n = 63) from the schizophrenia analyses. Replication sample. We analyzed the main effects of sex, age, birth weight, and genetic risk on social anhedonia and schizophrenia diagnosis using all available participants in the replication sample. The sample sizes in these analyses were 144 and 282 for analyses including social anhedonia and schizophrenia, respectively. Because of the limited number of participants in our replication study, birth weight was not categorized as “low” (i.e. less than 2.5 kg) or “high” (i.e. more than 4 kg), but studied as a continuous variable. The effect of birth weight on schizophrenia is assumedly U-shaped: both low and high birth weight has been associated with schizophrenia diagnosis (e.g. earlier study using NFBC1966: Moilanen et al., 2010). Accordingly, to avoid the effect of low and high birth weight canceling each other, we excluded all participants who had birth weight less than 2.5 kg from the interaction analyses (n = 26) to be able to analyze the effect of high birth weight. After the exclusion, we had 133 and 256 individuals in the analysis of social anhedonia and schizophrenia, respectively. Because the replication sample was derived from a family-based sample, in which the participants within one family cannot be considered as entirely independent observations, we used a General Estimating Equations (GEE) model in the analyses in order to adjust for the within-family correlations (Liang and Zeger, 1986). We used sex, age and information on which subsample the participant belonged to (Internal isolate or All Finland), as covariates in the analyses. Unfortunately we did not have data on mother’s BMI, gestational age, or genome-wide data to calculate the main principal components for the sample, and were not able to control for these variables in the replication analyses.

3. Results

3.1. Study group

Descriptions of the study sample are presented in Table 1. Men had higher birth weight (p < 0.001), higher scores on social anhedonia (p < 0.001), and more schizophrenia diagnosis than women (p = 0.02) as described earlier for this cohort (Miettunen et al., 2010). There was no difference in the genetic risk score, calculated from the 8 variants (Schizophrenia Psychiatric Genome-Wide Association Study GWAS Consortium, 2011) between the sexes (p = 0.40). Participants with schizophrenia diagnosis had higher scores on social anhedonia than non-schizophrenics (p < 0.001) as described earlier for this cohort (Miettunen et al., 2011).

We first examined the main effects of sex, high birth weight, genetic risk, and gestational age on social anhedonia in a linear regression model. Sex was significantly associated with social anhedonia (standardized β = −0.27, p < 0.001), so that men had higher scores, while high birth weight (standardized β = 0.03, p = 0.09), genetic risk (standardized β = −0.01, p = 0.34) or gestational age (standardized β
J. Luhanen et al.

3.2. Replication in the schizophrenia family sample

Descriptions of the replication sample are presented in Table 1. In the analysis of main effects of sex, age, birth weight, and genetic risk on social anhedonia in a linear regression model (n = 144), none of the variables had significant association with social anhedonia (sex p = 0.09, OR = 1.40, 95% CI: 0.95–2.05 for men having higher scores; birth weight p = 0.30, genetic risk p = 0.14, age p = 0.87). We also studied the main effects by excluding participants with a birth weight lower than 2.5 kg (n = 133). No significant association was seen between birth weight and social anhedonia (p = 0.78, OR = 1.03, 95% CI 0.84–1.3). The interaction between birth weight and genetic risk on social anhedonia in a fully adjusted regression model was non-significant (p = 0.09; OR = 1.1, 95% CI: 1.0–1.3), but in the same direction as in the original sample (participants having both higher genetic risk score and higher birth weight tended to have higher scores on social anhedonia than other participants).

The genetic risk score was not directly associated with schizophrenia diagnosis in the replication sample (p = 0.36). In a fully adjusted regression model, the interaction between genetic risk and birth weight was significantly associated with schizophrenia (p = 0.02; OR = 1.5, 95% CI: 1.1 – 2.1). Because the association in the primary sample was found particularly in women, we further performed the analysis separately in men and women. In men, the interaction was not significant (p = 0.93), while in women the interaction between genetic risk and birth weight was significantly associated with schizophrenia diagnosis so that having higher birth weight and higher genetic risk was associated with more schizophrenia diagnosis (OR = 2.0, 95% CI: 1.4 – 2.9, p < 0.001).

3.3. Results for the broader genetic risk score

Finally, we analyzed the broader genetic risk score comprised of 127 variants (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) in the study sample. The correlation between the narrower and broader genetic risk scores was low (r = 0.03, p = 0.03). As with the narrower genetic risk score there was no difference between the sexes (p = 0.13) and the genetic risk score did not correlate with the first main principal components (p-values from 0.22 to 0.70). In the analysis of main effects, we found no association between the broader genetic risk score and social anhedonia (standardized β = 0.02, p = 0.17); but it was associated with schizophrenia diagnosis (OR = 1.8, 95% CI: 1.2–2.7, p = 0.005) so that having higher genetic risk score increased the risk for schizophrenia. No change in the result was seen by including sex and three principal components as covariates in the analysis. In a fully adjusted regression model with broader genetic risk score there was no interaction between birth weight and genetic risk on social anhedonia (p = 0.61), or schizophrenia diagnosis (p = 0.24).

### Table 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>Study sample</th>
<th>Replication sample</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(NFBC1966)</td>
<td>(PSU)</td>
</tr>
<tr>
<td>Mean (SD) or % (N)</td>
<td>Mean (SD) or % (N)</td>
<td></td>
</tr>
<tr>
<td>Sex (% men)</td>
<td>45.0 (1902)</td>
<td>46.8 (132)</td>
</tr>
<tr>
<td>Age</td>
<td>31.0 (0)</td>
<td>45.6 (9.2)</td>
</tr>
<tr>
<td>Birth weight (kg)</td>
<td>2.47 (0.5)</td>
<td>3.40 (0.8)</td>
</tr>
<tr>
<td>High birth weight</td>
<td>11.5 (487)</td>
<td>16.7 (47)</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>40.1 (1.9)</td>
<td>no data</td>
</tr>
<tr>
<td>Social anhedonia</td>
<td>9.50 (5.6)</td>
<td>11.6 (7.1)*</td>
</tr>
<tr>
<td>Schizophrenia diagnosis</td>
<td>1.6 (81)</td>
<td>31.2 (88)</td>
</tr>
<tr>
<td>Genetic risk score</td>
<td>11.4 (1.8)</td>
<td>12.8 (1.6)</td>
</tr>
<tr>
<td>Broader genetic risk score</td>
<td>–0.50 (0.54)</td>
<td>no data</td>
</tr>
</tbody>
</table>

n for the schizophrenia analysis was 5033.  

### Table 2

Results of logistic regression analyses on schizophrenia diagnosis for all individuals, and men and women separately.

<table>
<thead>
<tr>
<th>Dataset</th>
<th>Genetic risk</th>
<th>Birth weight ≤ 4 kg</th>
<th>Birth weight &gt; 4 kg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR 95% CI</td>
<td>p n cases / n total</td>
<td>OR 95% CI</td>
</tr>
<tr>
<td>ALL</td>
<td>Low genetic risk</td>
<td>1.0 ref –</td>
<td>42 / 2757</td>
</tr>
<tr>
<td></td>
<td>High genetic risk</td>
<td>1.1 [0.7–1.9]</td>
<td>0.60 23 / 1323</td>
</tr>
<tr>
<td>MEN</td>
<td>Low genetic risk</td>
<td>1.0 ref –</td>
<td>24 / 1269</td>
</tr>
<tr>
<td></td>
<td>High genetic risk</td>
<td>0.9 [0.5–1.9]</td>
<td>0.87 11 / 622</td>
</tr>
<tr>
<td>WOMEN</td>
<td>Low genetic risk</td>
<td>1.0 ref –</td>
<td>18 / 1488</td>
</tr>
<tr>
<td></td>
<td>High genetic risk</td>
<td>1.4 [0.7–2.9]</td>
<td>0.37 12 / 701</td>
</tr>
</tbody>
</table>

The group with low genetic risk and birth weight ≤ 4 kg was used as the reference group. Sex, gestational age, mother’s BMI, and 3 PCAs were used as covariates in the analyses.

* Low genetic risk group includes the two lowest terciles of the genetic risk score.

* High genetic risk group is defined as the highest tercile of the genetic risk score.
4. Discussion

We found that the association between high genetic risk (Schizophrenia Psychiatric Genome-Wide Association Study GWAS Consortium, 2011) for schizophrenia and social anhedonia was stronger among those who had also perinatal risk factors as indicated by high birth weight. The same phenomenon was seen for schizophrenia itself, at least among women. These original results were found in a population-based birth cohort, and, we were able to find similar results in a schizophrenia patient sample. Although our replication study was not powered to assess birth weight as a dichotomous variable, the interaction we found between higher birth weight and genetic risk score on social anhedonia and schizophrenia argues for a true finding. However, we did not see the same interaction results when we used a broader genetic risk score (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) as a measure for genetic liability. We did see a direct association, however, between the genetic risk score and schizophrenia diagnosis.

We expected to find the same interaction results with both the narrower and broader risk scores, because it is plausible to think that the broader score would only contain more information on the genetic risk for schizophrenia. It is unclear, however, whether these two genetic scores reflect the same aspects of genetic liability for schizophrenia. Correlation between the narrower and the broader risk scores was very low, and, the narrower risk score, which was based on the results of the large schizophrenia GWAS in 2011, and the broader score, which was based on the results of the mega-GWAS of schizophrenia reported in 2014, do not share any variants in common. Five of the eight variants in the narrower score are within the 108 genomic areas reported in the 2014 GWA study, but three of them are not (although they are close).

A direct association was seen between the broader polygenic risk score (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) and schizophrenia diagnosis, so that participants with a higher genetic risk score carried a higher risk for schizophrenia diagnosis. This is an expected result that is also seen in other studies (e.g. Agerbo et al., 2015).

High birth weight has been associated in the NFBC1966 cohort with, for example, increased risk of perinatal mortality (Rantakallio, 1968), and it is itself likely to be a proxy of other adversities related to gestation and labor, such as prolonged labor, gestational diabetes and maternal hyperglycemia, which were not screened for at that time. The generalizability of the results to newer cohorts needs to be explored. Yet there is the possibility that the risk variants affect both birth weight and schizophrenia liability, but this also requires further exploration.

It is interesting that we saw the interaction result, considering schizophrenia, only in women. There are sex differences related to schizophrenia that are often reported: e.g. schizophrenia is more common in men than women, the onset of the disease is earlier in men than women, and differences in symptom patterns and cognitive functions (Pedersen et al., 2014; Abel et al., 2010b), although not all studies report similar findings (e.g. Saha et al., 2005). So far, though, there have not been many studies that consider possible different developmental pathways in schizophrenia between men and women. However, a hypothesis of sex-specific genetic risk for schizophrenia has been proposed and it has gained some support (Goldstein et al., 2013). In addition, "a female protective model" in neurodevelopmental disorders has been proposed and supported (Jacquemont et al., 2014). For example, Jacquemont et al. (2014) showed that women diagnosed with autism carry more deleterious genetic mutations compared to men and, as such, are able to tolerate a higher deleterious mutational load before becoming seriously ill. Whether this protective model is applicable to environmental insults as well is, to our knowledge, currently unknown.

In our study, women diagnosed with schizophrenia had more often both high genetic risk and high birth weight compared to men. Furthermore, it must be noted that the environmental risk factor used in this study was somewhat more extreme for women than for men, because the 4 kg cutoff for high birth weight deviates more from girls’ mean birth weight than from boys’ mean birth weight (Rantakallio, 1968).

There are limitations that need to be taken into account. As a population-based birth cohort, our sample suffers from a low number of schizophrenia patients, especially in the high birth weight group. Because of limited availability of information on birth weight, our replication sample is quite small. In addition, we lacked data on all the same covariates as in the original sample.

Our study has several strengths. As our discovery sample is a population-based birth cohort, it lacks the problems present in selected clinical samples. We were able to replicate our findings in a different type of sample, a patient sample, which is also not a selected clinical sample, but a systematically collected sample of Finnish schizophrenia families. Our measures of genetic risk, environment and outcomes were highly reliable. Schizophrenia diagnoses in both samples were based on validated register data and interviews. Our discovery sample is a prospectively followed cohort and, for example, birth weight was reported by the mothers very close to the actual birth. In the replication sample birth weights were acquired from health care registries, which are highly reliable in Finland.

In conclusion, our results highlight the role of the interplay between environmental and genetic risk factors in assessing the risk of schizophrenia. Failure to take environmental effects into account may be one of the reasons why identifying significant SNPs for schizophrenia in genome-wide analyses has been challenging. These results suggest a role for gene-environment interactions in schizophrenia and provide encouragement to pursue further G x E studies in schizophrenia.

Acknowledgment

JLI was supported by the Sigrid Juselius Foundation (work group grant/Jouko Lünqvist). JM was supported by grants from the Academy of Finland (project grant 268336), the Jalmari and Rauha Ahokas Foundation, and the Northern Finland Health Care Support Foundation. EK was supported by grants from the Academy of Finland, Finnish Foundation for pediatric research, Emil Aaltonen Foundation, Sigrid Juselius Foundation, and Novo Nordisk Foundation. NFBC1966 received financial support from the Academy of Finland (project grants 104781, 120315, 129269, 1114194, 24300796, Center of Excellence in Complex Disease Genetics and SALVE), University Hospital Oulu, Biocenter, University of Oulu, Finland (75617), NHLBI grant 5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01), NIH/NIMH (5R01MH63706-02), ENGAGE project and grant agreement HEALTH-F4-2007-201413, EU FP7 EurHEALTHAgeing – 277849 and the Medical Research Council, UK (G0500539, G0600705, G1002319, PrevMetSyn/SALVE). The Schizophrenia family sample received financial support from the Sigrid Juselius Foundation.

The DNA extractions, sample quality controls, biobank up-keeping and aliquoting was performed in the National Public Health Institute, Biomedicum Helsinki, Finland and supported financially by the Academy of Finland and Biocentrum Helsinki. We thank the late Professor Paula Rantakallio (launch of NFBC1966), and Ms Outi Tornwall and Ms Minttu Jussila (DNA biobanking). Genotyping of the Schizophrenia family sample was performed in the Technology Centre, Institute for Molecular Medicine Finland FIMM, University of Helsinki, Finland. We thank Kati Donner for the genotyping.

JS reports to have participated in research collaboration with Janssen-Cilag in 2011 and reports to have received honoraria for lecturing from AstraZeneca the same year. All other authors declare that they have no conflicts of interest.

References
